Tag: osé
OSE Immuno’s US partner, Veloxis, obtains fast track status for FR104
Veloxis plans to develop FR104 in order to provide a new therapeutic option in the prophylaxis of organ rejection in patients who have received a solid organ transplant. Less than…
OSE Immunotherapeutics co-opts Alexandre Lebeaut as independent director – 2022-02-18 at 18:15
(AOF) – OSE Immunotherapeutics has announced the appointment of Alexandre Lebeaut by cooptation as independent director of the Company. A doctor of medicine, Alexandre Lebeaut has more than 25 years…
Ose immuno: FDA Fast Track Designation for VEL-101
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
OSE Immunotherapeutics is pleased to announce FDA Fast Track Designation for CD28 antagonist VEL-101/FR104, granted by Veloxis Pharmaceuticals, Inc., its partner in transplantation – 02/17/2022 18:00
Nantes, France – February 17, 2022, 6:00 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that Veloxis Pharmaceuticals, Inc., a subsidiary of Asahi Kasei, has obtained “Fast Track”…
OSE Immuno: up after the announcements
Through Claude Leguilloux Published on 02/01/2022 at 11:01 Photo credit © Reuters (Boursier.com) — OSE Immuno climbed 7.3% on Tuesday to 8.80 euros, as the group announced the acceptance of…
OSE Immuno: FDA green light for Veloxis Pharmaceuticals
(CercleFinance.com) – OSE Immunotherapeutics announces that the United States Food & Drug Administration (FDA) has accepted the Investigational New Drug (IND) application formulated by Veloxis Pharmaceuticals for a clinical trial…
OSE Immunotherapeutics Receives First Grant of Patent for Use of Tedopi® After Failure of PD-1 or PD-L1 Checkpoint Inhibitor Treatment in HLA-A2 Positive Cancer Patients – 25 /01/2022 at 6:30 PM
A grant agreement issued by the Japanese Patent Office This new patent will protect Tedopi® until 2037 Nantes, France – January 25, 2022, 6:30 p.m. – OSE Immunotherapeutics SA (ISIN:…
OSE Immuno: under 10 euros
Through Hector Chaunu Published on 01/17/2022 at 11:00 a.m. This stock market news is for subscribers only Privileges Test our stock market advice for €1, without obligation I subscribe Already…
Ose immuno: Degroof Petercam maintains the purchase
Read also (CercleFinance.com) – Degroof Petercam renewed its buy recommendation on OSE Immuno on Monday, with a price target maintained at 15.5 euros, following the departure of CEO Alexis Peyroles…
OSE Immunotherapeutics announces the appointment of Dominique Costantini as interim Chief Executive Officer following the departure of Alexis Peyroles – 01/17/2022 at 07:30
Nantes, France – January 17, 2022, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces the departure of Alexis Peyroles as Chief Executive Officer of the Company. Dominique…
OSE Immuno appoints a transitional CEO, no impact according to an analyst firm
Subscribe for 1€ Unlimited access to all advice More than 800 stocks listed in Paris and abroad screened. To buy ? To sell ? What course objective? Our experts engage…
OSE Immunotherapeutics: appointment of Dominique Costantini as Chief Executive Officer – 01/17/2022 at 08:18
(AOF) – OSE Immunotherapeutics has announced the departure of Alexis Peyroles as CEO of the company. Dominique Costantini, currently Chair of the OSE Immunotherapeutics Board of Directors and Chief Executive…